---
document_datetime: 2023-09-21 19:58:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/mycamine-epar-all-authorised-presentations_en.pdf
document_name: mycamine-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8106937
conversion_datetime: 2025-12-20 17:18:12.309234
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EMEAProcedure number   | Invented name   | Strength   | Pharmaceutical Form                              | Route of administration   | Packaging    | Content (concentration)   | Package size   |
|------------------------|-----------------|------------|--------------------------------------------------|---------------------------|--------------|---------------------------|----------------|
| EMEA/H/C/734/001       | Mycamine        | 50 mg      | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 10 ml                     | 1 vial         |
| EMEA/H/C/734/002       | Mycamine        | 100 mg     | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 10 ml                     | 1 vial         |